Audiologic evaluation of Menière's disease patients one day and one week after intratympanic application of gadolinium contrast agent: Our experience in sixty‐five patients

Louza, Julia; Krause, Eike; Gürkov, Robert

doi:10.1111/coa.12087

Cited by 19 publications

(14 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results show no long‐term ototoxicity after the intratympanic use of GBCA for MRI. These results confirm the observations of previous studies analyzing hearing thresholds after GBCA, which showed no short‐term side effects or ototoxicity …”

Section: Discussionsupporting

confidence: 91%

“…Another follow‐up study evaluated the hearing function not only directly after application but also 1 week later. The results of this study with 65 patients having possible Ménière's disease showed no hearing deterioration …”

Section: Introductionmentioning

confidence: 60%

“…These results confirm the observations of previous studies analyzing hearing thresholds after GBCA, which showed no shortterm side effects or ototoxicity. 9,10 Animal studies from Tanaka et al 18 showed morphological changes such as shape changing, hair cell impairment, and cell shrinkage in vestibular end organs of bullfrogs after application of fourfold diluted GBCA. With the eightfold and sixteenfold dilution, the morphological changes were less frequent.…”

Section: Discussionmentioning

confidence: 99%

“…The results of this study with 65 patients having possible M enière's disease showed no hearing deterioration. 10 However, the long-term influence of GBCA on hearing function is still unknown. The aim of this study was to evaluate the long-term effects of GBCA on hearing function in patients with normal auditory thresholds.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Hearing function after intratympanic application of gadolinium‐based contrast agent: A long‐term evaluation

2015

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 60%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Hearing function after intratympanic application of gadolinium‐based contrast agent: A long‐term evaluation

2015

View full text Add to dashboard Cite

show abstract

“…No severe adverse effects were reported to date in the literature because of intratympanic administration of gadolinium. According to two studies of Louza et al (25,26), which showed no significant deterioration of hearing function in short-term after intratympanic gadolinium administration, the long-term follow up showed no evidence of ototoxicity either. The diagnostic value of bilateral (instead of unilateral) intratympanic gadolinium administration has been confirmed, even more since no ototoxicity or other adverse effects been reported.…”

Section: Discussionmentioning

confidence: 95%

Click Stimulus Electrocochleography Versus MRI With Intratympanic Contrast in Ménière's Disease

Ziylan

Smeeing²,

Stegeman³

et al. 2016

Otology &Amp; Neurotology

View full text Add to dashboard Cite

Objective: To evaluate the diagnostic value of electrocochleography compared with magnetic resonance imaging (MRI) with intratympanic gadolinium administration to diagnose endolymphatic hydrops in patients with Ménière's disease. Data Sources: An electronic search was performed in the PubMed, EMBASE, and Cochrane databases on September 15, 2015. A systematic search was conducted. Articles were included if written in English, Dutch, German, or French language. Study Selection: Original studies reporting on the diagnostic value of electrocochleography compared with MRI with intratympanic gadolinium administration, were included. Data Extraction: The methodological quality of the studies was independently assessed by two reviewers using an adjusted version of the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool. The results of the diagnostic values of both tests were extracted.Data Synthesis: We performed analyses for the sensitivity, specificity, positive predictive value, and negative predictive value of compared electrocochleography with MRI with intratympanic gadolinium administration in patients with definite Ménière's disease. Conclusion: The results of this systematic review, based on a very low number of patients, show there is a relative low sensitivity and negative predictive value for click stimulus electrocochleography compared with MRI with intratympanic gadolinium administration for detecting endolymphatic hydrops in patients with definite Ménière's disease.

show abstract

Magnetic resonance imaging and Ménière’s disease—unavoidable alliance

et al. 2021

View full text Add to dashboard Cite

Ménière's disease (MD) is a clinical syndrome characterized by recurrent episodes of spontaneous vertigo, unilateral fluctuating sensorineural hearing loss, tinnitus, and aural fullness. Endolymphatic hydrops is recognized as the pathophysiological substrate of the disease, having been demonstrated in anatomical pathological studies and more recently by magnetic resonance imaging (MRI). The current criteria of the disease, however, remain symptom based and do not include the demonstration of endolymphatic hydrops. The authors review MRI techniques and diagnostic criteria of endolymphatic hydrops and the role of MRI in MD is discussed.

show abstract

Audiologic evaluation of Menière's disease patients one day and one week after intratympanic application of gadolinium contrast agent: Our experience in sixty‐five patients

Cited by 19 publications

References 9 publications

Hearing function after intratympanic application of gadolinium‐based contrast agent: A long‐term evaluation

Hearing function after intratympanic application of gadolinium‐based contrast agent: A long‐term evaluation

Click Stimulus Electrocochleography Versus MRI With Intratympanic Contrast in Ménière's Disease

Magnetic resonance imaging and Ménière’s disease—unavoidable alliance

Contact Info

Product

Resources

About